Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Video

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.

What side effects of CAR T therapies are currently known?

Primary side effects of CAR T therapies occur early on after treatment and they’re related to the growth of the T cells and the actual activity of the T cells. So many patients will have fever and potentially progressing to more serious symptoms requiring hospital-level care and sometimes ICU-level care. Those symptoms typically resolve within the first week or sometimes within the first several weeks.

The main side effects of this therapy are within the first 28 days. But there’s lots of monitoring and potential for long-term side effects as well. Most patients are usually physically very well after the first month of treatment, but still require some focused monitoring for some of the on-target effects of CAR T cells, which involve B-cell aplasia. So, these patients, because of how CD19 CAR T cells work, will be depleted of their normal B cells, and that requires monitoring and replacement of the immunoglobulin long term.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.